LADENBURG THALM/SH SH reissued their buy rating on shares of Intec Pharma (NASDAQ:NTEC) in a research note issued to investors on Thursday, AnalystRatings.com reports.
“We know the AP-cannabis compounds are so oily they require a reservoir, which is unlike the two immediate-release (IR) and one extended-release (XR) films in AP-CD/LD. So again, the films are specific to the API. Management has described AP’s technology as uniquely suited to low soluble drugs, but we do not know if that describes either of the two major pharma’s proprietary drugs.”,” LADENBURG THALM/SH SH’s analyst wrote.
Several other research firms have also weighed in on NTEC. Oppenheimer set a $15.00 price objective on shares of Intec Pharma and gave the company a buy rating in a research report on Friday, February 22nd. Maxim Group restated a buy rating and set a $12.00 price objective on shares of Intec Pharma in a research report on Tuesday, February 19th. ValuEngine upgraded shares of Intec Pharma from a hold rating to a buy rating in a research report on Monday, February 4th. Zacks Investment Research upgraded shares of Intec Pharma from a sell rating to a hold rating in a research report on Tuesday, February 5th. Finally, BidaskClub upgraded shares of Intec Pharma from a buy rating to a strong-buy rating in a research report on Saturday, February 23rd. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. The stock currently has a consensus rating of Buy and a consensus price target of $12.17.
Shares of NASDAQ:NTEC traded down $0.16 during trading hours on Thursday, hitting $5.19. 196,384 shares of the company’s stock traded hands, compared to its average volume of 238,481. Intec Pharma has a 52 week low of $3.55 and a 52 week high of $9.25. The firm has a market cap of $173.32 million, a price-to-earnings ratio of -3.71 and a beta of 0.29.
Intec Pharma (NASDAQ:NTEC) last posted its quarterly earnings data on Tuesday, May 7th. The biotechnology company reported ($0.32) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.37) by $0.05. As a group, equities analysts forecast that Intec Pharma will post -1.06 earnings per share for the current year.
Several institutional investors and hedge funds have recently made changes to their positions in NTEC. PRW Wealth Management LLC acquired a new position in shares of Intec Pharma in the fourth quarter worth about $29,000. Reilly Financial Advisors LLC acquired a new position in shares of Intec Pharma in the fourth quarter worth about $38,000. BlackRock Inc. acquired a new position in shares of Intec Pharma in the fourth quarter worth about $67,000. Marshall Wace North America L.P. acquired a new position in shares of Intec Pharma in the first quarter worth about $117,000. Finally, Delek Group Ltd. acquired a new position in shares of Intec Pharma in the first quarter worth about $154,000. Institutional investors own 34.90% of the company’s stock.
Intec Pharma Company Profile
Intec Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing drugs based on its proprietary Accordion Pill platform technology in Israel. Its Accordion Pill is an oral drug delivery system that is designed to enhance the efficacy and safety of existing drugs and drugs in development by utilizing a gastric retention and specific release mechanism.
Featured Article: What is the Bid-Ask Spread?
Receive News & Ratings for Intec Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intec Pharma and related companies with MarketBeat.com's FREE daily email newsletter.